Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 15/20 | 0.64 |
| ▸ | CA1 | P00915 | 14/20 | 0.60 |
| ▸ | CA2 | P00918 | 14/20 | 0.60 |
| ▸ | CA12 | O43570 | 6/20 | 0.60 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.55 |
| ▸ | CA7 | P43166 | 2/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.49 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15557109 | 0.93 | CA9 (0.71) | CA9CA1CA2CA12CA14 | |
| SCHEMBL18163373 | 0.88 | CA9 (0.68) | CA9CA1CA2CA12CA14 | |
| SCHEMBL18517643 | 0.88 | CA9 (0.70) | CA9CA1CA2CA12CA14 | |
| SCHEMBL17522975 | 0.84 | CA9 (0.73) | CA9CA1CA2CA12CA14 | |
| SCHEMBL17522976 | 0.83 | CA9 (0.49) | CA9CA1CA2CA12CA14 | |
| SCHEMBL18559017 | 0.82 | CA9 (0.60) | CA9CA1CA2CA12CA14 | |
| SCHEMBL16521412 | 0.82 | CA9 (0.68) | CA9CA1CA2CA12CA14 | |
| SCHEMBL14089616 | 0.82 | CA9 (0.73) | CA9CA1CA2CA12CA14 | |
| SCHEMBL21728989 | 0.81 | CA9 (0.73) | CA9CA1CA2CA12CA14 | |
| SCHEMBL21151146 | 0.81 | CA9 (0.73) | CA9CA1CA2CA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160046584-A1 | COMPOSITIONS AND METHODS OF USING THE COMPOSITIONS FOR PLAQUE SOFTENING | ALUMEND, LLC (US) | 2016-02-18 | — | — | US | disclosed |
| US-20160046584-A1 | COMPOSITIONS AND METHODS OF USING THE COMPOSITIONS FOR PLAQUE SOFTENING | ALUMEND, LLC (US) | 2016-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046584-A1 | COMPOSITIONS AND METHODS OF USING THE COMPOSITIONS FOR PLAQUE SOFTENING | APOB, PLG, LIPG | CA9 781/4885CA1 502/4885CA2 898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.